Gastroesophageal Reflux Disease Therapeutics Market Report 2025

The gastroesophageal reflux disease therapeutics market size has grown steadily in recent years. It will grow from $5.93 billion in 2024 to $6.14 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to changing lifestyles and dietary habits, aging population, increased awareness and diagnosis, prevailing stressful lifestyles, rise in obesity rates.

The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.89 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rise in demand for novel therapies, growing geriatric population, personalized medicine approaches, focus on non-pharmacological interventions, emergence of biologics and innovative therapies. Major trends in the forecast period include alternative therapies and mind-body practices, expanded research into gut health, advent of patient-centric care models, targeted marketing for gerd awareness, integration of digital health tools.

The anticipated growth in the gastroesophageal reflux disease therapeutics market is expected to be driven by the prevalence of gastroesophageal reflux disease. This chronic condition, characterized by the backflow of stomach acid into the esophagus, leads to symptoms such as heartburn and regurgitation. Gastroesophageal reflux disease (GERD) therapeutics are designed to reduce and manage these symptoms by neutralizing gut pH, controlling inflammation, and improving esophageal function. For example, a WebMed article in September 2022 reported that over 60 million American adults experience heartburn at least once a month, with more than 15 million experiencing daily symptoms. Additionally, the National Library of Medicine shared statistics in July 2022 indicating GERD's high prevalence of 20% in the United States, causing a significant economic burden and impacting quality of life. Hence, the increasing prevalence of gastroesophageal reflux disease is expected to fuel the growth of the therapeutics market.

The adoption of self-medication is playing a significant role in the continued growth of the gastroesophageal reflux disease therapeutics market. Self-medication involves using drugs or substances to treat a medical condition without consulting a healthcare professional. This practice is beneficial for individuals in identifying and managing trigger foods, handling stress, and quitting smoking, all of which contribute to improving GERD symptoms. A survey conducted in May 2022 by Lippincott Williams & Wilkins, involving 170 participants, revealed that 57.7% practiced self-medication, and 34.7% felt no need to consult a medical practitioner. Therefore, the adoption of self-medication is expected to be a driving factor in the gastroesophageal reflux disease therapeutics market.

Product innovations are a key trend gaining traction in the gastroesophageal reflux disease (GERD) therapeutics market. Major companies in this sector are concentrating on developing innovative medications to maintain their competitive edge. For instance, in November 2023, Phathom Pharmaceuticals, a US-based biopharmaceutical company, launched VOQUEZNA (vonoprazan), a potassium-competitive acid blocker approved for the healing and maintenance of all grades of erosive esophagitis, as well as for alleviating heartburn associated with both erosive and non-erosive GERD. Clinical trials demonstrated impressive results, with a healing rate of 93% in patients treated with the 20 mg dosage, compared to 85% for the standard proton pump inhibitor (PPI) lansoprazole. This innovation highlights the ongoing commitment to advancing treatment options in the GERD market.

Major companies in the gastroesophageal reflux disease therapeutics market are directing their efforts toward the development of innovative systems, including wireless pH-capsule reflux testing systems. These medical devices are specifically designed for diagnosing and monitoring gastroesophageal reflux disease (GERD) and related conditions. For instance, in April 2023, Laborie Medical Technologies Corp., a U.S.-based medical testing equipment manufacturer, introduced the alpHaONE system, a wireless pH-capsule reflux testing system tailored for GERD diagnosis. Offering up to 96 hours of data monitoring, this system ensures accurate and reliable data. The alpHaONE system features an ergonomic and compact design, user-friendly enlarged buttons, and a fail-safe capsule delivery system designed to protect the patient's esophagus.

In October 2022, Evonik Industries AG, a Germany-based specialty chemicals company, entered into a partnership with Phathom Pharmaceuticals. This collaboration aims to enable Evonik to produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in the United States and Germany. Phathom Pharmaceuticals, a U.S.-based biopharmaceutical company, is dedicated to developing innovative medicines for stomach acid-related disorders, including drugs for gastroesophageal reflux disease.

Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited.

North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastroesophageal reflux disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastroesophageal reflux disease (GERD) therapeutics encompass medications designed for the chronic medical condition characterized by the upward movement of stomach contents into the esophagus, leading to symptoms such as heartburn and regurgitation. These therapeutics aim to neutralize and diminish the production of stomach acid, maintaining an optimal pH level in the gut and preventing the backflow of fluids into the stomach that causes acid reflux.

The primary categories of gastroesophageal reflux disease therapeutics include branded and generic medications. Branded medications are those that can only be dispensed with a prescription from a physician or other authorized prescriber, adhering to state or federal regulations. These drugs are employed for the treatment of gastroesophageal reflux disease, aiming to alleviate symptoms and facilitate esophageal healing. Various drug classes, such as antacids, proton pump inhibitors, histamine blockers, pro-kinetic agents, among others, are distributed through diverse channels, including hospital pharmacies, drug stores, general stores, and supermarkets. These therapeutics find applications in conditions such as Crohn’s disease, gastroesophageal reflux disease (GERD), and ulcerative colitis.

The gastroesophageal reflux disease therapeutics market research report is one of a series of new reports that provides gastroesophageal reflux disease therapeutics market statistics, including gastroesophageal reflux disease therapeutics industry global market size, regional shares, competitors with a gastroesophageal reflux disease therapeutics market share, detailed gastroesophageal reflux disease therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gastroesophageal reflux disease therapeutics industry. This gastroesophageal reflux disease therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroesophageal reflux disease (GERD) therapeutics market consists of sales of amino-salicylates (5-ASA), corticosteroids, immunomodulators, antibiotics, biologics, and dopamine receptor antagonist. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.